JP2009046472A - Emulsified composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an emulsified composition having effects of inhibiting adhesion of Staphylococcus aureus to the skin and maintaining humidity, and useful for treating, preventing or improving symptoms caused by dry skin and/or diseases expressing symptoms caused by dry skin (particularly, atopic dermatitis and the like). <P>SOLUTION: The emulsified composition comprises (A) Vaseline, (B) lecithin, (C) glycerol, and (D) prednisolone valerate acetate. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention has an effect of suppressing the adhesion of Staphylococcus aureus to the skin and a moisturizing effect, and is a disease (particularly, atopic symptom) caused by symptoms of dry skin and / or symptoms caused by dry skin. The present invention relates to an emulsified composition containing petrolatum, lecithin, glycerin, and prednisolone valerate acetate, which is useful for treatment, prevention or improvement of dermatitis etc.).

  Staphylococcus aureus has long been strongly involved in atopic dermatitis because the pathogenic bacterium Staphylococcus aureus is detected in skin lesions of patients with atopic dermatitis at a high rate and high concentration. Has been suggested. Today, atopic dermatitis is also one of the social problems, so studies to clarify the significance of Staphylococcus aureus in the skin lesions have been conducted energetically, but there are still many unclear points. . However, the fact that Staphylococcus aureus is detected at a high rate and high concentration from the skin lesions in atopic dermatitis indicates that Staphylococcus aureus is deeply involved in the pathogenesis and exacerbation of atopic dermatitis. It is shown. Therefore, various countermeasures against Staphylococcus aureus have been proposed for the purpose of improving the condition of the skin surface of patients with atopic dermatitis.

  For example, Patent Document 1 discloses that glucooligosaccharide has an effect of suppressing the adhesion of Staphylococcus aureus to the skin surface, or a skin external preparation or skin cosmetic containing glucooligosaccharide is used on the skin surface of atopic dermatitis patients. It is disclosed that it can be improved and is useful.

By the way, prednisolone valerate acetate is classified into rank III (strong) in the efficacy rank classification of steroids, and exhibits excellent local anti-inflammatory action, but is rapidly metabolized to a less active compound after absorption in the blood. It is a drug with high safety and relatively few side effects. Although an external preparation for skin containing this prednisolone valerate acetate is known (see Patent Documents 2 to 3), there is no description or suggestion about the effect of the external preparation for adhesion to the skin of Staphylococcus aureus. Further, the moisturizing effect, the therapeutic effect on atopic dermatitis, the itching reduction effect and the like of the external preparation for skin are not clear.
Japanese Patent Laying-Open No. 2005-2087 JP 2005-350379 A JP 2005-32057 A

  Diseases that have the effect of inhibiting the adhesion of Staphylococcus aureus to the skin and the moisturizing effect, and exhibit symptoms caused by dry skin and / or symptoms caused by dry skin (especially atopic dermatitis, etc.) It is an object of the present invention to provide an emulsified composition useful for treatment, prevention or improvement. Furthermore, another object of the present invention is to provide an emulsified composition having a stagnation reducing effect.

  The inventors of the present invention have an emulsion composition containing petrolatum, lecithin, glycerin, and prednisolone valerate acetate having an inhibitory effect on Staphylococcus aureus adhesion and an excellent moisturizing effect. It has been found that the emulsified composition is useful for treating, preventing or ameliorating symptoms caused by skin dryness and / or diseases (especially atopic dermatitis etc.) showing symptoms caused by dry skin. Furthermore, it has also been found that the emulsified composition has an effect of reducing stagnation, and the present invention has been completed.

Accordingly, the present invention provides the following.
[1] (A) Vaseline,
(B) lecithin,
An emulsified composition containing (C) glycerin and (D) prednisolone valerate acetate.
[2] The emulsified composition according to the above [1], wherein the content of (A) petrolatum is 10 to 30% by weight based on the total amount of the emulsified composition.
[3] The emulsion composition according to [1] or [2], wherein the content of (C) glycerin is 10 to 20% by weight with respect to the total amount of the emulsion composition.
[4] The emulsion composition according to any one of [1] to [3], further comprising a water-soluble polymer.
[5] The water-soluble polymer is composed of a cellulose polymer, a vinyl polymer, an acrylic acid polymer, a plant polymer, a microbial polymer, a polymer having a phospholipid polar group, and a mucopolysaccharide. The emulsified composition according to the above [4], which is at least one selected from the group.
[6] Further, non-steroidal anti-inflammatory agents, vitamins, whitening agents, anti-wrinkle agents, anti-inflammatory analgesics, antifungal agents, steroid agents, hair restorers, slimming agents, local anesthetics, antipruritic agents, antibacterial agents, anti [1] to [1] above containing at least one selected from the group consisting of a virus agent, a keratin softener, a moisturizer, an astringent, an antioxidant, a hair growth inhibitor, an ultraviolet absorber, and an ultraviolet scattering agent. [5] The emulsion composition according to any one of [5].
[7] The above [1] to [5], further comprising at least one active ingredient selected from the group consisting of a nonsteroidal anti-inflammatory agent, a local anesthetic, an antipruritic agent and a moisturizing agent. ] The emulsion composition in any one of.
[8] The emulsified composition according to any one of [1] to [7], which is used for suppressing adhesion of Staphylococcus aureus to the skin.
[9] Any of the above-mentioned [1] to [7], which is used for treatment, prevention or amelioration of a symptom caused by skin dryness and / or a disease showing a symptom caused by dry skin An emulsified composition according to any one of the above.
[9] The emulsified composition according to any one of the above [1] to [6], which is used for treatment, prevention or improvement of atopic dermatitis.

According to the present invention, Staphylococcus aureus has an anti-adhesion effect on the skin and an excellent moisturizing effect, and also exhibits symptoms caused by dry skin and / or symptoms caused by dry skin ( In particular, a novel composition containing petrolatum, lecithin, glycerin, and prednisolone valerate acetate that is useful for the treatment, prevention or improvement of atopic dermatitis and the like is provided.
Since the composition of the present invention is excellent in moisturizing properties, it can be used for treatment, prevention, or improvement of symptoms (especially atopic dermatitis, etc.) that show symptoms caused by dry skin and / or symptoms caused by dry skin. It is useful as a composition for the purpose. Moreover, since the composition of this invention also has the outstanding stagnation reducing effect, it is useful also as a composition for stagnation reduction.

  Hereinafter, the present invention will be described in detail. It should be understood that the terms used in the present specification are used in the meaning normally used in the art unless otherwise specified.

Vaseline used in the present invention is a semi-solid product obtained by purifying a mixture of hydrocarbons, and is not particularly limited as long as it is commonly used in pharmaceuticals, quasi drugs, and cosmetics. Can do.
In the present invention, either yellow petrolatum or white petrolatum may be used, but white petrolatum having a low impurity content is preferable from the viewpoint of hypoallergenicity and the like.

  The blending amount of petrolatum in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but usually 10 to 30% by weight, preferably 12 to 27% by weight, in particular, with respect to the whole emulsion composition (100% by weight). Preferably it is 15-25 weight%. When the blending amount of petrolatum in the present invention is less than 10% by weight, the blocking property (reduction of moisture transpiration) is inferior, and when it exceeds 30% by weight, not only the feeling of use is deteriorated but also the expected blocking property (reduction of moisture transpiration) Property) is not obtained.

  The lecithin used in the present invention is a mixture of phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol, and components such as triglycerides, fatty acids, and carbohydrates from vegetable oils. Although it varies greatly depending on the degree of purification, chemical treatment, etc., it can be used without particular limitation as long as it is usually used in pharmaceuticals, quasi drugs, and cosmetics.

  The lecithin used in the present invention may be natural lecithin derived from animals and plants (for example, soybean lecithin, egg yolk lecithin, etc.), lecithin obtained by chemical treatment of natural lecithin, or a solvent such as acetone from natural lecithin. It may be lecithin in which the content of phosphatidylcholine is increased by purification with The content of phosphatidylcholine in the lecithin used in the present invention is not particularly limited.

Examples of lecithin obtained by chemically treating natural lecithin include hydrogenated lecithin obtained by hydrogenation treatment (for example, fully hydrogenated lecithin and partially hydrogenated lecithin), and hydroxylated lecithin obtained by hydroxylation treatment. Etc. Furthermore, the lecithin used in the present invention may be a lyso form of the natural lecithin or chemically treated lecithin. However, since the lyso form is easily oxidized, if the lyso form is used, the storage stability of the emulsified composition of the present invention is lowered and irritation may occur, so that lecithin is preferably not a lyso form.
These lecithins can be used singly or in combination of two or more.

  Specific examples of lecithin used in the present invention include soybean lecithin, egg yolk lecithin, purified soybean lecithin, purified egg yolk lecithin, hydrogenated soybean lecithin, egg yolk lysophosphatidylcholine, soybean lysophospholipid and the like.

The blending amount of lecithin in the present invention is not particularly limited as long as the effect of the present invention is exhibited, but is usually 0.1 to 5% by weight, preferably 0.5 to 3% by weight, particularly preferably based on the whole emulsion composition. Is 1.2 to 2% by weight. If it is less than 0.1% by weight, emulsification tends to be difficult, and if it exceeds 5% by weight, odor and coloring may occur.
Furthermore, the blending amount of lecithin in the present invention is preferably 5 to 30% by weight, and 10 to 20% by weight with respect to 100% by weight of petrolatum, from the viewpoint of emulsion stability and usability of the emulsion composition of the present invention. It is more preferable that

  The glycerin used in the present invention can be used without particular limitation as long as it is usually used in pharmaceuticals, quasi drugs, and cosmetics.

The blending amount of glycerin in the present invention is not particularly limited as long as the effects of the present invention are exerted, but is usually 1 to 30% by weight, preferably 5 to 25% by weight, particularly preferably 10 to 20% with respect to the whole emulsion composition. % By weight. If it is less than 1% by weight, the moisturizing effect may be insufficient, and if it exceeds 30% by weight, the sticky feeling tends to increase.
Furthermore, the blending amount of glycerin in the present invention is preferably 20 to 200% by weight, and preferably 30 to 150% by weight with respect to 100% by weight of petrolatum, from the viewpoint of the moisturizing effect of the emulsion composition of the present invention. More preferred.

The prednisolone valerate acetate used in the present invention (hereinafter sometimes simply referred to as “PVA”) is a known compound and can be used without particular limitation as long as it is commonly used in pharmaceuticals and quasi drugs. it can.
Prednisolone valerate acetate may be synthesized by a known method or may be obtained as a commercial product.

  The blending amount of prednisolone valerate in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but is usually 0.03 to 0.3% by weight, preferably 0.15 to 0, based on the whole emulsion composition. .3% by weight. If the amount is less than 0.03% by weight, the effect of the present invention is not sufficiently exhibited. If the amount exceeds 0.3% by weight, a problem of side effects may occur.

The emulsified composition of the present invention preferably contains a water-soluble polymer from the viewpoint of emulsion stability and usability.
The water-soluble polymer used in the present invention is not particularly limited as long as it is usually used in pharmaceuticals, quasi drugs and cosmetics.
The water-soluble polymer may be in the form of a salt. Examples of the salt of the water-soluble polymer include alkali metal salts such as sodium and potassium; alkaline earth metal salts such as magnesium and calcium;

Specific examples of the water-soluble polymer used in the present invention include:
Cellulosic polymers such as methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carmellose sodium, stearoxyhydroxypropylmethylcellulose;
Vinyl polymers such as polyvinyl alcohol (partially saponified product), polyvinyl pyrrolidone, polyethylene glycol, carboxyvinyl polymer, polyvinyl methyl ether, N-acryloyldimethyltaurine ammonium / vinyl pyrrolidone copolymer;
Acrylic polymer such as sodium polyacrylate, partially neutralized polyacrylic acid, acrylic acid / methacrylic acid alkyl ester copolymer (for example, Pemulen (registered trademark));
Plant polymers such as gum arabic, gum tragacanth, galactan, guar gum, pectin, carrageenan, alginic acid, sodium alginate, propylene glycol alginate;
Microbial polymers such as xanthan gum, dextran, pullulan;
Mucopolysaccharides such as chondroitin sulfate, sodium chondroitin sulfate, hyaluronic acid, sodium hyaluronate;
A polymer having a phospholipid polar group such as MPC polymer (for example, LIPIDURE (registered trademark));
Etc. These water-soluble polymers can be used alone or in combination of two or more.

As the water-soluble polymer used in the present invention,
Polyvinyl alcohol (partially saponified product), polyvinyl pyrrolidone, polyethylene glycol, carboxyvinyl polymer, polyvinyl methyl ether, N-acryloyldimethyltaurine ammonium vinylpyrrolidone copolymer;
Sodium polyacrylate, partially neutralized polyacrylic acid, acrylic acid / methacrylic acid alkyl ester copolymer (for example, Pemulen (registered trademark), etc.);
Gum arabic, gum tragacanth, galactan, guar gum, pectin, carrageenan, alginic acid, sodium alginate;
Xanthan gum, dextran, pullulan;
Chondroitin sulfate, sodium chondroitin sulfate, hyaluronic acid, sodium hyaluronate;
A carboxyvinyl polymer, an acrylic acid / methacrylic acid alkyl ester copolymer (for example, Pemulen (registered trademark)), propylene glycol alginate, xanthan gum, hyaluronic acid, sodium hyaluronate, and the like are particularly preferable.

The blending amount of the water-soluble polymer in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but is usually 0.0001 to 5% by weight, preferably 0.001 to 3% by weight, based on the whole emulsion composition. More preferably, it is 0.01-3 weight%, Most preferably, it is 0.01-1 weight%.
Furthermore, the blending amount of the water-soluble polymer in the present invention is preferably 0.1 to 10% by weight with respect to 100% by weight of petrolatum from the viewpoint of emulsification stability and feeling of use of the emulsion composition of the present invention. It is more preferably 1 to 7% by weight, and particularly preferably 2 to 4% by weight.

The emulsified composition of the present invention may further contain water. The blending amount of water in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but it is usually 40 to 75% by weight, preferably 60 to 75% by weight, particularly preferably 60 to 70%, based on the entire emulsion composition. % By weight.
Furthermore, the blending amount of water in the present invention is preferably 250 to 550% by weight, preferably 400 to 500% by weight with respect to 100% by weight of petrolatum, from the viewpoint of emulsion stability and usability of the emulsion composition of the present invention. It is more preferable that

  The emulsified composition of the present invention can further contain an active ingredient in order to give the composition a desired effect. In the present invention, the active ingredient is an ingredient having a useful effect on the skin such as a pharmacologically active ingredient or a physiologically active ingredient, and is not particularly limited. For example, non-steroidal anti-inflammatory agents, vitamins, whitening agents, anti-wrinkle agents are used. Agent, anti-inflammatory analgesic agent, antifungal agent, steroid agent, hair restorer, slimming agent, local anesthetic agent, antipruritic agent, antibacterial agent, antiviral agent, keratin softener, moisturizer, astringent, antioxidant, hair growth inhibition Agents, ultraviolet absorbers, ultraviolet scattering agents and the like. These components can be used individually by 1 type or in combination of 2 or more types.

  Further, the blending amounts of these components are not particularly limited as long as the effects of the present invention are achieved, but can be appropriately selected and used within the pharmaceutically acceptable upper limit blending amount.

Specifically, the following components can be exemplified.
Non-steroidal anti-inflammatory agents: licorice extract, glycyrrhizic acid, glycyrrhizic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate; glycyrrhetinic acid or derivatives thereof; allantoin or derivatives thereof; indomethacin; ibuprofen; ibuprofen piconol; Butyl fenfenate; bendazac; piroxicam; ketoprofen; felbinac; salicylic acid derivatives such as methyl salicylate or glycol salicylate; menthol;

Vitamins: retinol, retinol acetate, retinol palmitate, retinal, retinoic acid, methyl retinoic acid, ethyl retinoic acid, retinoic acid retinol, vitamin A fatty acid ester, d-δ-tocopheryl retinoate, α-tocopheryl retinoate, vitamins A such as β-tocopheryl retinoate;
provitamins A such as β-carotene, α-carotene, γ-carotene, δ-carotene, lycopene, zeaxanthin, cryptoxanthin, echinone;
Vitamin E such as α-tocopherol, β-tocopherol, δ-tocopherol, tocopherol acetate, dl-α-tocopherol succinate, dl-α-tocopherol calcium succinate;
Vitamin B2 such as riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, sodium riboflavin 5'-phosphate, riboflavin tetranicotinate;
Nicotinic acids such as methyl nicotinate, nicotinic acid, nicotinamide;
Ascorbic acid stearate, L-ascorbyl dipalmitate, ascorbyl tetraisopalmitate, ascorbic acid, sodium ascorbate, dehydroascorbic acid, sodium ascorbate phosphate, magnesium ascorbate phosphate, magnesium ascorbate phosphate Vitamin C such as sodium ascorbic acid phosphate, ascorbic acid glucoside;
Vitamin Ds such as methyl hesperidin, ergocalciferol, cholecalciferol;
Vitamin Ks such as phylloquinone and farnoquinone;
γ-oryzanol, dibenzoyl thiamine, dibenzoyl thiamine hydrochloride, thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, Vitamins B1 such as thiamine monophosphate, thiamine monophosphate, thiamine diphosphate, thiamine diphosphate, thiamine triphosphate, thiamine triphosphate monophosphate;
Vitamin B6s such as pyridoxine hydrochloride, pyridoxine acetate, pyridoxal hydrochloride, 5′-pyridoxal phosphate, pyridoxamine hydrochloride;
Vitamins B12 such as cyanocobalamin, hydroxocobalamin, deoxyadenosylcobalamin;
Folic acids such as folic acid and pteroylglutamic acid;
Pantothenic acids such as pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-pantetheine, D-panthetin, coenzyme A, pantothenyl ethyl ether;
Biotins such as biotin and bioticin;
Vitamin-like agents such as carnitine, ferulic acid, α-lipoic acid, orotic acid.

  Whitening agent: Placenta; Arbutin; Cysteine; Ellagic acid; Kojic acid; Phytic acid; Lucinol; Hydroquinone; Iris (iris), Almond, Aloe, Ginkgo, Oolong tea, Ages, Ogon, Ouren, Hypericum, Odoricho, Seaweed, Cascon, Camomile , Licorice, gardenia, kujin, wheat, rice, rice haiga, oryzanol, rice bran, perilla, peonies, cucumber, soy, peas, soybean, tea, terminaria, cypress, red snapper, scallop, safflower, safflower, buttonpi, yokuinin, enoki, p ), Components derived from plants such as clove, extracts and essential oils.

  Anti-wrinkle agent: ubiquinone such as coenzyme Q6-10, kinetin, glycolic acid, aldiline, acylated glucosamine, collagen, hyaluronic acid, aloe extract, seaweed extract, maronier extract, rosemary extract, cornflower extract and the like.

  Anti-inflammatory analgesics: indomethacin, ferbinac, methyl salicylate, glycol salicylate, allantoin or derivatives thereof, ibuprofen, ibuprofen piconol, bufexamac, butyl flufenamic acid, bendazac, piroxicam, ketoprofen and the like.

  Antifungal agents: terbinafine hydrochloride, sulconazole nitrate, clotrimazole, isoconazole nitrate, croconazole nitrate, miconazole nitrate, econazole nitrate, oxyconazole nitrate, bifonazole, thioconazole, ketoconazole, tolnaphthalate, tolcyclate, lilanaphthalate, ciclopirox olamine, exeramamide Siccanin, undecylenic acid, zinc undecylenate, pyrrolnitrin, butenafine hydrochloride, amorolfine hydrochloride, neticonazole hydrochloride and the like.

  Steroids: dexamethasone acetate dexamethasone acetate, dexamethasone propionate, dexamethasone propionate, dexamethasone acetate, dexamethasone valerate, hydrocortisone butyrate, hydrocortisone acetate, hydrocortisone, hydrocortisone butyrate propionate, cortisone acetate, prednisolone acetate, prednisolone acetate, betamethasone betamethasone Betamethasone acid, clobetasone butyrate, clobetasol propionate, diflorazone acetate, diflucortron valerate, beclomethasone propionate, flumethasone pivalate, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, amsinonide, halcinonide, difluprednate, etc.

  Hair restorer: procyanidin, dipotassium glycyrrhizinate, capronium chloride, cephalanthin, menthol, hinokitiol, L-hydroxyproline, acetylhydroxyproline, fucoidan, capsicum tincture, sultianine, symphonginicin, flavonosteroid, minoxidil, FGF-10, enmeiso extract (Extract), assembly extract (extract), beetroot extract (extract), flax extract (extract), hypericum extract (extract), gentian extract (extract), sage extract (extract), peppermint extract ( Extract), hop extract (extract), yokuinin extract (extract), coconut leaf extract (extract), ginger extract (extract), carrot extract (extract), body extract (extract), button Such as pin extract (extract).

  Slimming agents: xanthines such as caffeine, aminophylline, theophylline, oxtriphyrin, diphylline, diisobutylaminobenzoyloxypropyltheophylline, theobromine, diprofylline, proxyphylline, pentoxyphylline; capsaicin and the like.

  Local anesthetics: lidocaine, lidocaine hydrochloride, dibucaine, dibucaine hydrochloride, ethyl aminobenzoate, eucalyptus oil, eugenol, camphor, mint oil, turpentine oil, etc.

  Antipruritics: crotamiton, chlorpheniramine, chlorpheniramine maleate, diphenhydramine, diphenhydramine hydrochloride, diphenhydramine salicylate, salicylic acid, nonylic acid vanillylamide, mequitazine, camphor, thymol, eugenol, polyoxyethylene lauryl ether, comfrey extract, perilla extract, etc.

  Antibacterial agents: isopropylmethylphenol, chlorhexidine gluconate, chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, cetyltrimethylammonium bromide, decalinium chloride, triclosan, trichlorocarbanilide and the like.

  Antiviral agents: acyclovir, penciclovir, etc.

  Keratin softener: Ethyl alcohol, isopropyl alcohol, propanol, butanol, polyethylene glycol, benzyl alcohol, phenylethyl alcohol, propylene carbonate, hexyl decanol, allantoin, dimethyl sulfoxide, dimethylacetamide, dimethylformamide, triethanolamine, diisopropyl adipate, ethyl Laurylate, lanolin, fatty acid dialkyrolamide, urea, sulfur, resorcin, phytic acid, lactic acid, lactate, sodium hydroxide, potassium hydroxide, etc.

  Moisturizer: hyaluronic acid or its salt, hyaluronic acid derivative (for example, acetyl hyaluronic acid) or its salt, polyethylene glycol, diglycerin trehalose, heparin analog, chondroitin sulfate sodium, collagen, elastin, keratin, chitin, chitosan, etc. Molecular compounds: amino acids such as glycine, aspartic acid, arginine, natural moisturizing factors such as sodium lactate, urea, sodium pyrrolidonecarboxylate, etc .; chamomile extract, aloe extract, aloe vera extract, hamamelis extract, rosemary extract, thyme extract, tea extract, perilla extract Extracts from plants such as ceramides such as ceramide 1, ceramide 2, ceramide 3, ceramide 4, ceramide 5, ceramide 6I, ceramide 6II, ceramide 7, etc., N- (hexadecyloxyhi Rokishipuropiru) -N- hydroxyethyl deca cyanamide, such as N- (hexadecene siloxy hydroxypropyl) -N- hydroxyethyl hexadecanol cyanamide.

  Astringent: citric acid, tartaric acid, lactic acid, aluminum chloride, aluminum sulfate, allantoinchlorohydroxyaluminum, allantoindihydroxyaluminum, aluminum phenolsulfonic acid, zinc paraphenolsulfonic acid, zinc sulfate, zinc lactate, aluminum chlorohydroxide and the like.

  Antioxidants: Dibutylhydroxytoluene, butylhydroxyanisole, disodium ethylenediaminetetraacetate dihydrate (hereinafter also referred to as sodium edetate), sorbic acid, sodium sulfite and the like.

  Hair growth inhibitor: isoflavone, cypress extract, docami extract, iris root extract, papain enzyme, etc.

  Ultraviolet absorber: 2-methoxyhexyl paramethoxycinnamate, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester, 2,4,6-tris [4- (2-ethylhexyloxycarbonyl) anilino ] -1,3,5-triazine, 2-ethylhexyl dimethoxybenzylideneoxoimidazolidinepropionate, 2,4-bis-[{4- (2-ethylhexyloxy) -2-hydroxy} -phenyl] -6- (4 -Methoxyphenyl) -1,3,5-triazine and the like.

  Ultraviolet light scattering agent: Inorganic compounds such as zinc oxide, titanium oxide, iron oxide, cerium oxide, zirconium oxide, titanium silicate, zinc silicate, anhydrous silicic acid, cerium silicate, and those inorganic compounds such as mica and talc Coated with inorganic powder, compounded with resin powder such as polyamide, polyethylene, polyester, polystyrene, nylon, etc., further treated with silicon oil, fatty acid aluminum salt, etc.

Among the above components, the emulsion composition of the present invention comprises a non-steroidal anti-inflammatory agent, a local anesthetic agent, an antipruritic agent and a moisturizer because the emulsion composition of the present invention is used for treatment, prevention or improvement of skin diseases. It is preferable to blend at least one active ingredient selected from the group.
From the viewpoint of reducing moisture transpiration from the skin, which is essential for xeroderma, it is preferable to add a heparin-like substance or urea used as a moisturizing agent to the emulsion composition of the present invention. .
Among these, heparin-like substances are particularly preferable because they are frequently used in the treatment of atopic dermatitis, where it is important to reduce moisture transpiration from the skin.
Further, from the viewpoint of prevention of inflammation due to drying, it is preferable to use a non-steroidal anti-inflammatory agent that is widely used.
Among these, menthol, camphor, dipotassium glycyrrhizinate, and allantoin, which are generally widely used from the viewpoint of safety, are particularly preferable.
In addition, when considering a remedy for itching due to dryness, it is preferable to add crotamiton, diphenhydramine or a salt thereof used as an antipruritic agent to suppress itching.
Among these, the commonly used blend of crotamiton is particularly preferable.

  The emulsified composition of the present invention has a quantitative and qualitative range within the quantitative and qualitative range so as not to impair the storage stability, the quality such as the viscosity, and the effect of the present invention. Various components commonly used in the field, such as a base, a preservative, a pH adjuster, a stabilizer, an irritation reducing agent, an antiseptic, a colorant, a dispersant, a fragrance, and a surfactant other than lecithin. Can be blended. In addition, these components can be mix | blended individually by 1 type or in combination of 2 or more types. Further, the blending amounts of these components are not particularly limited as long as the effects of the present invention are achieved, but are desirably selected as appropriate with the upper limit blending amount acceptable for pharmacology.

As the base,
Hydrocarbons such as paraffin, ozokerite, ceresin, hard fat, microcrystalline wax, squalane (synthetic / vegetable), α-olefin oligomer, liquid paraffin, light isoparaffin, liquid isoparaffin, polyethylene powder;
Fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, linoleic acid;
Tri fatty acid glycerides such as glyceryl tri-2-ethylhexanoate (trioctanoin);
Highly polymerized methyl polysiloxane, dimethyl polysiloxane, dimethyl siloxane methyl (polyoxyethylene) siloxane methyl (polyoxypropylene) siloxane copolymer, dimethyl siloxane methyl (polyoxyethylene) siloxane copolymer, dimethyl siloxane methyl (Polyoxypropylene) siloxane copolymer, polyoxyethylene / methylpolysiloxane copolymer, poly (oxyethylene / oxypropylene) / methylpolysiloxane copolymer, dimethylsiloxane / methylcetyloxysiloxane copolymer, dimethylsiloxane・ Methyl stearoxy siloxane copolymer, alkyl acrylate copolymer methyl polysiloxane ester, cross-linked methyl polysiloxane, cross-linked methyl phenyl polysiloxane, cross-linked poly Ether-modified silicone, crosslinked alkyl polyether-modified silicone, polymerization type silicone, such as cross-linked alkyl-modified silicone;
Glycol acetates such as ethylene glycol monoacetate, ethylene glycol diacetate, triethylene glycol diacetate, hexylene glycol diacetate, and 2-methyl-2-propene-1,1-diol diacetate;
Glycol esters such as triethylene glycol divalerate, 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, 2,2,4-trimethyl-1,3-pentanediol diisobutyrate;
Glycol acrylates such as ethylene glycol diacrylate, diethylene glycol diacrylate, propylene glycol monoacrylate, 2,2-dimethyl-trimethylene glycol diacrylate, and 1,3-butylene glycol diacrylate;
Glycol dinitrates such as ethylene glycol dinitrate, diethylene glycol dinitrate, triethylene glycol dinitrate, and propylene glycol dinitrate;
Ether compounds such as 2,2 ′-[1,4-phenylenedioxy] diethanol, dioxane, butylene glycol adipic acid polyester;
Lower alcohols such as ethanol and isopropanol;
Higher alcohols such as cetanol, stearyl alcohol, behenyl alcohol, cetostearyl alcohol, hexyldecanol, isostearyl alcohol, octyldodecanol, oleyl alcohol, decyltetradecanol, myristyl alcohol;
Polyhydric alcohols (excluding glycerin) such as ethylene glycol, propylene glycol, 1,3-butylene glycol, 1,2-pentanediol, 1,2-hexanediol;
Diethylene glycol alkyl ethers such as diethylene glycol monoethyl ether;
Macro goal;
Esters such as isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, glyceryl tri-2-ethylhexylate, glyceryl monostearate, medium chain fatty acid triglycerides;
Polyoxyethylene alkyl ethers such as polyoxyethylene behenyl ether;
And vegetable oils such as olive oil.

  Surfactants other than the lecithin include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, diglycerol sorbitan penta-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate Sorbitan fatty acid esters such as sorbitan sesquioleate; glyceryl fatty acids such as glyceryl monostearate and glyceryl monostearate; polyglyceryl fatty acids such as polyglyceryl monoisostearate and polyglyceryl diisostearate; propylene glycol monostearate, etc. Propylene glycol fatty acid esters of polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene Hardened castor oil derivatives such as hardened castor oil 80; polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene monostearate (20) sorbitan (polysorbate 60), polyoxyethylene monooleate (20) Polyoxyethylene sorbitan fatty acid esters such as sorbitan (polysorbate 80); polyoxyethylene alkyl ethers such as polyoxyethylene behenyl ether, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether; polyoxyethylene polyoxypropylene cetyl ether Polyoxyethylene polyoxypropylene alkyl ether; polyoxyethylene fatty acid ester such as polyoxyl stearate; macrogol stearate; Bruno phosphorus alcohols, polyoxyethylene mono coconut oil fatty acid glyceryl, glycerin alkyl ethers, alkyl glucosides, stearylamine, etc. oleylamine and the like.

  Examples of the preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, benzyl paraoxybenzoate, Examples include methyl paraoxybenzoate and phenoxyethanol.

  Examples of the pH adjuster include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, and boric acid; lactic acid, acetic acid, citric acid, tartaric acid, malic acid, succinic acid, sodium succinate, oxalic acid, gluconic acid, and fumaric acid. Organic acids such as acid, propionic acid, acetic acid, aspartic acid, epsilon-aminocaproic acid, glutamic acid, and aminoethylsulfonic acid; gluconolactone; ammonium acetate; sodium hydrogen carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, hydroxylated Examples include inorganic bases such as calcium and magnesium hydroxide; organic bases such as monoethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, and lysine.

The average particle size of the inner phase of the emulsion composition of the present invention is not particularly limited, but the average particle size measured based on the Mie theory is usually 5000 nm or less, preferably 2000 nm or less, particularly preferably 1000 nm or less. The lower limit of the average particle size is usually 50 nm, preferably 100 nm, particularly preferably 200 nm.
In order to obtain an emulsified composition having an average particle size of less than 50 nm, more energy is required, and in order to emulsify, it may be necessary to use a surfactant having high emulsifying power but high irritation. May be unfavorable from the viewpoint of reducing sexuality and irritation. Moreover, when an average particle diameter is larger than 5000 nm, it may be unpreferable from a viewpoint of stability, a usability | use_condition, and moisture retention.

The average particle size of the inner phase of the emulsified composition of the present invention is automatically determined by Mie scattering theory from scattered light data measured using a laser diffraction / scattering particle size distribution analyzer (for example, HORIBA LA-920). This means the median diameter obtained by calculation. The median diameter is a particle diameter corresponding to a cumulative frequency distribution of 50%.
An emulsified composition is an emulsion. In this specification, an emulsion is a liquid in which one of two liquids that are not mixed with each other is formed into droplets and dispersed in the other liquid. Moreover, the internal phase of an emulsion composition refers to the said droplet.

Further, when the emulsion composition of the present invention further contains a water-soluble polymer, the average particle size of the inner phase of the emulsion composition of the present invention cannot be measured by the measurement based on the above Mie theory. It is possible by measurement based on the dynamic light scattering theory by the dynamic light scattering method. In the Mie theory, the particle size distribution is calculated by observing and analyzing the intensity distribution of the scattered light. In the dynamic light scattering theory, the particle size distribution is calculated by observing and analyzing the fluctuation of the intensity distribution due to the interference of the scattered light. .
The average particle size of the inner phase of the emulsion composition of the present invention measured by this dynamic light scattering method based on the dynamic light scattering theory is not particularly limited, but is usually 800 nm or less, preferably 700 nm or less, particularly preferably. 500 nm or less. When the average particle diameter exceeds 800 nm, the feeling of use and stability of the emulsion composition are lowered. The lower limit of the average particle diameter is not particularly limited, but is usually 10 nm, preferably 50 nm, more preferably 100 nm, and particularly preferably 150 nm.
In this case, the average particle size of the inner phase of the emulsified composition is determined based on dynamic light based on scattered light data measured by a batch measurement method using a laser diffraction / scattering particle size distribution analyzer (for example, Otsuka Electronics FPAR-1000). It means the median diameter obtained by automatically calculating the particle size distribution by the scattering theory. The median diameter is a particle diameter corresponding to a cumulative frequency distribution of 50%.

The preparation method of the emulsified composition of the present invention is not particularly limited. For example, the components (A) to (D) constituting the emulsified composition of the present invention, and (E) component, water, active ingredient, base, etc. The emulsified composition of the present invention is obtained by emulsifying the mixture of the various components.
Here, as a method for the emulsification treatment, components (A) to (D) constituting the emulsified composition of the present invention, and optionally a mixture of various components such as component (E), water, active ingredient, and base are used. , And emulsification processing with strong energy using an emulsifier (such as a microfluidizer, ultrasonic emulsifier, high-pressure emulsifier (high-pressure homogenizer), etc.) that can apply stronger energy than a homomixer. . By the emulsification treatment, the emulsified composition of the present invention having an average particle diameter satisfying a desired range, for example, the above range can be obtained.
In addition, the whole quantity of (A)-(D) component which comprises the emulsion composition of this invention, and various components, such as (E) component, water, an active ingredient, and a base, may be emulsified, and a case Depending on the case, it is possible to further blend the remaining components after emulsifying only a part of the components. Whether the entire amount is emulsified or only a part is emulsified and then the remaining components are blended may be appropriately selected depending on the raw materials to be blended.

  The emulsion composition thus obtained can be either an oil-in-water type or a water-in-oil type, but is preferably an oil-in-water type. Generally, when the blending amount of water is 40% by weight or more with respect to 100% by weight of the emulsified composition, there is a tendency to become an oil-in-water type.

  The emulsified composition of the present invention can be prepared in various forms. For example, forms, such as cream, milky lotion, and gel milky lotion, are mentioned. Especially, since it is easy to apply | coat in a wide range, as an embodiment of this invention, an emulsion is preferable.

Although the viscosity in 25 degreeC of the emulsion composition of this invention is not restrict | limited in particular, Usually, it is 500-30000 mPa * S. The viscosity at 25 ° C. of the emulsion composition of the present invention is preferably 800 to 10,000 mPa · S, and particularly preferably 1000 to 5000 mPa · S.
When the viscosity is greater than 30000 mPa · s, the feeling of use, for example, ease of spreading on the skin (ease of application) and stickiness may be inferior. Further, when the viscosity is less than 500 mPa · s, the storage stability may be inferior.

In this specification, the viscosity means that the emulsified composition is put in a glass 50 ml screw mouth bottle, and a BL type viscometer (manufactured by Toki Sangyo Co., Ltd.) is used to select an optimal rotor and rotation speed for the viscosity. This is the value obtained by measurement.
The measurement method will be described in more detail. When the viscosity of the emulsified composition is 500 mPa · s or more and less than 4500 mPa · s, it means a value when measured with an M2 rotor at 25 ° C., a rotation speed of 6 rpm, after 1 minute. When the viscosity of the emulsified composition is 4500 mPa · s or more and less than 18000 mPa · s, it means a value measured at 25 ° C., a rotational speed of 6 rpm for 1 minute with an M3 rotor. When the viscosity of the emulsified composition is 18000 mPa · s to 30000 mPa · s, it means a value measured at 25 ° C. with a rotation speed of 12 rpm for 1 minute after passing through an M4 rotor.

  In addition, when the viscosity cannot be measured due to slipping of the emulsion composition or exceeding the upper limit of measurement in the viscosity measurement, those having a hardness of 1000 g or less have the value measured by the following measuring method as the viscosity. The hardness of the emulsified composition was measured by placing the emulsified composition in a plastic 50 g jar and measuring the hardness with a rheometer. The maximum value until the 1 cm approach of the bottom of the adapter when measured under the conditions of Speed (UP) 2 cm / min and φ20 (compression elasticity) adapter.

  The application amount and usage of the emulsified composition of the present invention to the outer skin are not particularly limited, and the composition can be used by applying an appropriate amount to the outer skin such as skin several times a day.

  The emulsified composition of the present invention only needs to belong to the category of pharmaceuticals and quasi drugs having various uses, and can be used as a composition for treating, preventing or improving various symptoms.

The use of the emulsion composition of the present invention includes, for example, use for treatment, prevention or amelioration of symptoms caused by skin dryness.
Specific examples of symptoms caused by dry skin include desquamation of the skin surface, dusting, bristle, roughness, cracks, scratches, keratinization of elbows, knees, heels and ankles, facial fine lines, skin There are a decrease in flexibility, finger tingling, itching, dry skin, sensitive skin, skin irritation, erythema, atopic skin, rough skin, and the like.
Specific diseases that show these symptoms include xeroderma, senile xeroderma, acne vulgaris (skin skin), childhood dry skin, atopic dermatitis, allergic dermatitis, sebum-reducing eczema, Sensitive skin, seasonal xeroderma, aqueous pruritus, housewife eczema.

  The emulsified composition of the present invention is particularly useful for the treatment, prevention or improvement of atopic dermatitis because it has an effect of suppressing the adhesion of Staphylococcus aureus to the skin in addition to the moisturizing effect as shown in the following test examples. It is.

  In general, the skin showing dry symptoms has a reduced barrier function. Since the emulsified composition of the present invention has excellent moisturizing properties, it provides moisture to the skin and is useful for the treatment, prevention or improvement of dry skin symptoms, and can increase the barrier function of the skin accordingly. For this reason, the emulsified composition of the present invention also has effects such as preparing the skin; adjusting the texture of the skin; keeping the skin healthy; protecting the skin;

  Furthermore, since the emulsified composition of the present invention has an excellent itch reduction effect, it is also useful for the treatment, prevention, or improvement of causes of itch (eg, rash, insect bites, rashes, hives, etc.).

  EXAMPLES The present invention will be specifically described below with reference to examples, but these examples do not limit the scope of the present invention. In addition, especially a compounding quantity does not have a unit description, all represent weight%.

Example 1
Vaseline, lecithin, ceramide and prednisolone valerate acetate were mixed and dissolved by heating to 75-80 ° C. On the other hand, after mixing a part of water, glycerin, and a preservative, and heating at 75-80 degreeC, in addition to the mixture of the said petrolatum and a lecithin, it premixed with the homomixer. The resulting mixture was emulsified by cooling with a high-pressure homogenizer at a pressure of 500 bar while the temperature was kept at 75 to 80 ° C., and cooled. By mixing xanthan gum and a pH adjuster dissolved in the remainder of water, an emulsion composition having the composition shown in Table 1 was obtained.

Test Example 1 Staphylococcus aureus Adhesion Test on Skin The inhibition of S. aureus adhesion of each sample was evaluated by a tape stripping method. The test was conducted at n = 4-5.

  Comparative Example 1 having the composition shown in Table 2 below was produced in the same manner as in Example 1 except that prednisolone valerate acetate was not added.

Staphylococcus aureus (ATCC 6538 strain) was inoculated on the surface of a soybean casein digest agar plate medium and cultured at 33 ° C. for 24 hours. The cultured cells are suspended in 5 mL of PBS (sterilized) to prepare a bacterial suspension containing about 1 × 10 ¹⁰ CFU / mL viable bacteria and diluted in stages to give about 1 × 10 ⁶ CFU / mL of live cells. A bacterial suspension containing the bacteria was prepared.

Human upper arm keratinocytes were collected on a 1 cm × 2 cm square double-sided tape (trade name “Nystack”: Nichiban Co., Ltd.) affixed to the tip of a slide glass. On this cell layer, each sample was applied with a platinum loop. Regarding the coating amount, Example 1 and Comparative Example 1 each had 20 mg, and Comparative Example 2 had PVA (0.03 mg; equivalent to 20 mg of PVA in Example 1) and water (13 mg; 20 mg of Example 1). Comparative Example 3 was applied with water (13 mg; equivalent to 20 mg of water in Example 1). After applying the sample, the sample was dried for 20 minutes, and the prepared 1 × 10 ⁶ cfu / mL bacterial solution (10 μL) was applied onto the sample. After drying, the surface of the tape was rinsed with PBS, and the number of remaining bacteria on the tape was applied using a microorganism medium sheet (trade name “Sani Tai-kun”: Azumax Co., Ltd.) and applied with bacteria according to the instructions. The count after the day was evaluated as the number of bacteria attached to the tape. A control was prepared by performing the same operation except that the sample was not applied.

The average number of counts is shown in Table 1 as the number of adherent bacteria. Moreover, the adhesion inhibition rate (%) of each group was calculated by the following formula and displayed in Table 3.
Bacterial adherence inhibition rate (%) = (1−number of adherent bacteria of sample / number of adherent bacteria of control group) × 100

  As shown in Table 3, Example 1, which is a composition of the present invention, adheres more than any of Comparative Example 1 that does not contain PVA, Comparative Example 2 that contains water and PVA, and Comparative Example 3 that contains only water. It was found that the number of bacteria was small and the adhesion of Staphylococcus aureus to human upper arm keratinocytes collected on an adhesive tape on a slide glass was suppressed.

Test Example 2 Moisturizing Test The normal skin (2 cm × 2 cm) of the upper arm inner skin (2 cm × 2 cm) was used as a test site, and the moisture retention was evaluated by measuring the amount of horny water after application of the test preparation.
Specifically, in a constant temperature and humidity measurement chamber (room temperature 21 ± 1 ° C., relative humidity 50 ± 3%), the test site is exposed and acclimated for 15 minutes, and then the test preparation (8 mg) is evenly applied to the test site. The high frequency conductivity (μS) of the test site and the non-coated control site after 5 minutes, 1 hour, 3 hours, and 6 hours before coating was measured with SKICON-200EX (manufactured by IBM). The measurement was performed 5 times at each test site, and the average value of 3 times was calculated. Table 4 shows the average value of the high-frequency conductivity (μS). In addition, it shows that a moisturizing effect is so high that the value of high frequency conductivity is large.
The preparation of Example 1 was used as a test preparation, and creams, lotions and ointments made by Kowa Co., Ltd. containing PVA and petrolatum were used as comparative examples. However, none of the preparations used as comparative examples contains lecithin and glycerin.

  As shown in Table 4, Example 1, which is the composition of the present invention, has improved high-frequency conductivity in all after 5 minutes, 1 hour, 3 hours, and 6 hours after application, compared to before application. That is, the amount of stratum corneum was increased. Furthermore, Example 1 which is the composition of the present invention has high-frequency conductivity in all of 5 minutes, 1 hour, 3 hours and 6 hours after application, even when compared with the comparative example containing PVA and petrolatum. That is, the amount of stratum corneum was increased. From the above, it was revealed that the composition of the present invention has an excellent moisturizing effect.

Test Example 3 Efficacy Test for Atopic Dermatitis by Humans 59 Adult males and females who are diagnosed with atopic dermatitis according to the definition and diagnostic criteria of atopic dermatitis and are moderate to mild and aged 20 to under 60 A test was conducted on the subjects to evaluate the effectiveness of the preparation of Example 1 against atopic dermatitis.

〔Test method〕
The preparation of Example 1 was continuously applied to the test site 2 to 3 times a day for 2 weeks.
[Observation evaluation items and observation date]
Before application, 1 week, and 2 weeks, the degree of each of the skin findings (erythema, papules / edema, moist / crust, erosion, lichenization / eruption, desquamation / dryness) is divided into 4 levels (3 : Moderate, 2: Mild, 1: Minor, 0: None).
Moreover, the subjective symptoms of itching were evaluated by the VAS method before application and after 2 weeks. Here, the VAS method is a method of measuring the subjective symptoms of itchiness by plotting the itchiness according to the degree of itchiness at that time, with a minimum itch of 0 mm and a maximum of 100 mm on a 100 mm scale.

  The scores of skin findings (erythema, papules / edema, wet / scab, erosion, lichenization / rash, desquamation / dry) are shown in Table 5 and FIG. The determination before application and after 2 weeks was performed with n = 59, and the determination after 1 week was performed with n = 40.

As shown in Table 5 and FIG. 1, for all skin findings, score improvement was recognized with a significant difference after 1 week and 2 weeks after application.
Regarding subjective symptoms of itching, the average value before application was 4.5, whereas the average value after 2 weeks of application was 1.3 ** (**: P <0.01 (t-test). It was confirmed that the composition of the present invention also has an effect of reducing itchiness.

The clinical trial results of 59 patients were extremely effective 30.5%, effective 54.2%, and slightly effective 15.3%.
As described above, it was confirmed that the emulsified composition of the present invention is useful for the treatment, prevention or improvement of atopic dermatitis and has a itch reduction effect.

  Examples of pharmaceutical formulations are given below, but the present invention is not limited to these examples.

It is a figure which shows transition of the skin finding score according to a symptom.

Claims (1)

(A) Vaseline,
(B) lecithin,
An emulsified composition containing (C) glycerin and (D) prednisolone valerate acetate.